These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Lebbe C, Beyeler C, Gerber NJ, Reichen J. Ann Rheum Dis; 1994 Jul; 53(7):475-7. PubMed ID: 7944622 [Abstract] [Full Text] [Related]
23. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Hussain MA. Biopharm Drug Dispos; 1998 Apr; 19(3):163-7. PubMed ID: 9569999 [Abstract] [Full Text] [Related]
26. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, Moreno Muelas JV, Pérez Sandoval T, Quijada Carrera J, Trenor Larraz P, Zea Mendoza A. Reumatol Clin; 2015 Apr; 11(1):3-8. PubMed ID: 24746914 [Abstract] [Full Text] [Related]
27. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. J Rheumatol; 1999 Dec; 26(12):2539-43. PubMed ID: 10606360 [Abstract] [Full Text] [Related]
28. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Aliment Pharmacol Ther; 2003 Jul 01; 18(1):57-63. PubMed ID: 12848626 [Abstract] [Full Text] [Related]
29. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Clin Pharmacokinet; 2016 Dec 01; 55(12):1547-1558. PubMed ID: 27272171 [Abstract] [Full Text] [Related]
30. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. Yukawa E, Mori S, Ueda K, Nakada Y. J Clin Pharm Ther; 2007 Dec 01; 32(6):573-8. PubMed ID: 18021334 [Abstract] [Full Text] [Related]
31. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. Schwartz JI, Agrawal NG, Wong PH, Miller J, Bachmann K, Marbury T, Hoelscher D, Cavanaugh PF, Gottesdiener K. J Clin Pharmacol; 2009 Oct 01; 49(10):1202-9. PubMed ID: 19783714 [Abstract] [Full Text] [Related]
32. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. Br J Clin Pharmacol; 1996 Aug 01; 42(2):195-200. PubMed ID: 8864317 [Abstract] [Full Text] [Related]
33. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators. Arthritis Care Res (Hoboken); 2015 Dec 01; 67(12):1627-36. PubMed ID: 25623393 [Abstract] [Full Text] [Related]
34. [Low dose methotrexate therapy in chronic polyarthritis--an update]. Leeb BF, Smolen JS. Acta Med Austriaca; 1996 Dec 01; 23(4):114-9. PubMed ID: 9036721 [Abstract] [Full Text] [Related]
35. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, Chales GH, Juvin RR, Lafforgue P, Le Parc JM, Tavernier CG, Meyer OC. Ann Pharmacother; 2004 Oct 01; 38(10):1582-7. PubMed ID: 15340127 [Abstract] [Full Text] [Related]
36. Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics. Methaneethorn J, AlEjielat R, Leelakanok N. Drug Metab Pers Ther; 2022 Sep 01; 37(3):229-240. PubMed ID: 35218177 [Abstract] [Full Text] [Related]
37. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis. Monjanel-Mouterde S, Lafforgue P, Blanc A, Catalin J, Aquaviva PC, Durand A. J Rheumatol; 1998 Jul 01; 25(7):1276-81. PubMed ID: 9676756 [Abstract] [Full Text] [Related]
38. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Tuková J, Chládek J, Nemcová D, Chládková J, Dolezalová P. Clin Exp Rheumatol; 2009 Jul 01; 27(6):1047-53. PubMed ID: 20149329 [Abstract] [Full Text] [Related]
39. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE. J Pharm Sci; 1989 Feb 01; 78(2):165-71. PubMed ID: 2715941 [Abstract] [Full Text] [Related]
40. Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study. Dhaon P, Das SK, Srivastava R, Agarwal G, Asthana A. Int J Rheum Dis; 2018 May 01; 21(5):1010-1017. PubMed ID: 27455886 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]